STUDY PROTOCOL
Published on 11 Nov 2025
Effect of angiotensin II receptor blockers on efficacy and safety of Camrelizumab plus chemotherapy in the first-line therapy for advanced non-small cell lung cancer (ARMOR I): a protocol for a prospective, real-world, multicenter, intervention clinical trial
doi 10.3389/fimmu.2025.1668782
- 230 views
